Guilty by association?
This article was originally published in Scrip
To very little fanfare of any kind, the International Federation of Pharmaceutical Manufacturers & Associations held its 25th Assembly this week in Washington, DC. In what appears to be a moment of high introspection, even for an introspective organisation like IFPMA, Dr Haruo Naito, CEO of Eisai and the retiring President of IFPMA concluded his remarks at the Assembly by trying to define the organisation's role.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.